| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000003708 |
| Receipt No. | R000004396 |
| Official scientific title of the study | A feasibility study of adjuvant therapy with FOLFOX plus Ca/Mg for the patient with colorectal cancer |
| Date of disclosure of the study information | 2010/07/14 |
| Last modified on | 2017/04/30 (Ver. 17) |
| Basic information | ||
| Official scientific title of the study | A feasibility study of adjuvant therapy with FOLFOX plus Ca/Mg for the patient with colorectal cancer | |
| Title of the study (Brief title) | A feasibility study of adjuvant therapy with FOLFOX plus Ca/Mg for the patient with colorectal cancer(KSCC0903) | |
| Region |
|
|
| Condition | |||
| Condition | Colorectal Cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To evaluate the safety of adjuvant treatment with a combination of FOLFOX plus Ca/Mg for the patient with colorectal cancer |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase IV |
| Assessment | |
| Primary outcomes | the rate of completion of treatment as planned |
| Key secondary outcomes | Safety (especially peripheral neuropathy, digestive symptom )
Quality of life Disease free survival Overall survival |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | FOLFOX4(L-OHP85mg/m2,l-LV100mg/m2x2, 5FU400mg/m2(bolus)x2, 5FU600mg/m2x2(civ)) or mFOLFOX6(L-OHP85mg/m2, l-LV200mg/m2, 5FU400mg/m2(bolus), 5FU2400mg/m2(civ)).
Ca/Mg 0.8-1g (iv) x2 before and after L-OHP infusion Cycles of therapy are given every 2 weeks for 12 cycles |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Written informed consent
2.Appropriate for the study at the physician's assessment 3.Histologically confirmed adenocarcinoma of the colon or rectum.(the tumor above the peritoneal reflection )(except appendix) 4.Histological high risk StageII and Stage III colorectal adenocarcinoma. 5.Tumor resection with D2orD3 lymph node dissection was performed. 6.Resection of histological curability A was performed 7.Aged 20<= years. 8.ECOG performance status of 0-1. 9.No prior chemotherapy and radiotherapy 10.Recovery of postoperative complications 11.Required baseline laboratory parameters (within 14 days before registration): WBC more than 3000 and WBC less than 12000/mm3 Neu more than 1,500/mm3 Plt more than 100,000/mm3 Hb more than 9.0g/dl T-Bil less than 2.0mg/dl AST,ALT within 2.5 times of normal limit of each hospital Cre less than 1.5mg/dl 12.Registration within 8 weeks after surgery |
|||
| Key exclusion criteria | 1.Patients who had received blood transfusion, blood products, or hematopoietic growth factors such as granulocyte-colony stimulating factor within 7 days prior to registration.
2.History of the severe hypersensitivity. 3.Sensory neuropathy. 4.Active other malignancies. 5.Active infection 6.History of mental disorder,central nerve disorder. 7.Watery stools or Grade 2 or more diarrhea 8.Requiring steroid drug 9.Pregnant or lactating woman 10.Co-mobility, such as interstitial lung disease, lung fibrosis, intestinal paralysis, ileus,uncontrolled diabetes, liver cirrhosis, viral hepatitis type B ,kidney failure, uncontrolled hypertension, history of cardiac infarction 11.History of the internal organ transplant 12.Hypercalcemia ,renal calculus 13.Requiring cardiac glycoside 14.High probability of recurrence 15.Not appropriate for the study at the physician's assessment |
|||
| Target sample size | 48 | |||
| Research contact person | |
| Name of lead principal investigator | Tadashi Nishimaki |
| Organization | University of the Ryukyus Faculty of Medicine |
| Division name | Department of Surgery Medicine |
| Address | 207 Uehara, Nishiharacho, Nakagamigun, Okinawa, 903-0215, Japan |
| TEL | 092-631-2920 |
| kscc2@cres-kyushu.or.jp | |
| Public contact | |
| Name of contact person | KSCC |
| Organization | Clinical Research Support Center Kyushu |
| Division name | KSCC |
| Address | 3-1-1, Maidashi, Higashi-Ku, Fukuoka, Japan, 812-8582 |
| TEL | 092-631-2920 |
| Homepage URL | |
| kscc2@cres-kyushu.or.jp | |
| Sponsor | |
| Institute | Kyushu Study group of Clinical Cancer |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Clinical Research Support Center Kyushu |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 九州大学(福岡県)
貝塚病院(福岡県) 国立病院機構九州医療センター(福岡県) 公立学校共済組合九州中央病院(福岡県) 済生会福岡総合病院(福岡県) 新日鐵八幡記念病院(福岡県) 国立病院機構福岡東医療センター(福岡県) 社会保険田川病院(福岡県) 社会保険仲原病院(福岡県) 久留米大学(福岡県) 久留米大学医療センター(福岡県) 社会保険久留米第一病院(福岡県) 公立八女総合病院(福岡県) 福岡大学(福岡県) 済生会八幡総合病院(福岡県) 麻生飯塚病院(福岡県) 済生会唐津病院(佐賀県) 健康保険諫早総合病院(長崎県) 佐世保市立総合病院(長崎県) 長崎大学(長崎県) 白十字会 佐世保中央病院(長崎県) 国立病院機構長崎医療センター(長崎県) 春回会 井上病院(長崎県) 光晴会病院(長崎県) 長崎百合野病院(長崎県) 医理会 柿添病院(長崎県) 熊本大学(熊本県) 高野会 高野病院(熊本県) 済生会熊本病院(熊本県) 熊本赤十字病院(熊本県) 熊本中央病院(熊本県) 大分赤十字病院(大分県) 国立病院機構大分医療センター(大分県) 国立病院機構別府医療センター(大分県) 中津市立中津市民病院(大分県) 大分県立病院(大分県) 潤愛会 鮫島病院(鹿児島県) 鹿児島大学(鹿児島県) 鹿児島厚生連病院(鹿児島県) 鹿児島共済会南風病院(鹿児島県) 済生会川内病院(鹿児島県) 浦添総合病院(沖縄県) 中頭病院(沖縄県) 沖縄県立南部医療センター・こども医療センター(沖縄県) 琉球大学(沖縄県) 北部地区医師会病院(沖縄県) 豊見城中央病院(沖縄県) ハートライフ病院(沖縄県) 広島赤十字・原爆病院(広島県) 松山赤十字病院(愛媛県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004396 |